BACKGROUND: Amikacin monotherapy is recommended for urinary tract infection (UTI) treatment with multi-resistant pathogens. Even though amikacin efficacy in the treatment of UTIs is dependent on its urinary concentration, there are no robust data proving that sufficiently high urinary concentration is reached in patients with reduced glomerular filtration rate (GFR). METHODS: A prospective study to monitor amikacin penetration into urine of 70 patients [40 males, median (interquartile range) age 70 (65-79) years] with different levels of glomerular filtration decline, including patients treated by dialysis, was conducted. The bactericidal efficacy of amikacin in urine samples has been evaluated. RESULTS: Patients with estimated GFR (eGFR) <30 mL/min had significantly lower median amikacin urinary concentration than patients with eGFR >30 mL/min (89.75 vs 186.0 mg/L, P < .0001; 200.5 vs 830.0 mg/L, P < .0001; and 126.0 vs 408.0 mg/L, P < .0001 for minimal, maximal and minimal together with maximal concentrations, respectively). The amount of amikacin eliminated in the first 10-13 h after dose administration was dependent on eGFR (r2 = 0.6144, P < .0001). The urinary concentration of amikacin in patients treated by dialysis was indirectly proportional to pH of urine. The plasma concentrations of amikacin did not correlate with urinary levels in patients in either of the GFR categories. Microbiological evaluation showed that the critical urinary concentration for efficacy of amikacin during UTI monotherapy in patients treated by dialysis is 100 mg/L. We found that 4 out of 11 patients treated by dialysis did not reach this level during the treatment. CONCLUSION: Systemic administration of amikacin monotherapy in patients treated by dialysis is questionable as the concentrations of amikacin in their urine are often below the threshold of effectivity. Amikacin plasma concentrations are not a major determinant of amikacin concentration in urine, therefore pulse dosing is neither necessary nor safe in patients treated by dialysis, and may cause undesirable toxicity.

3rd Department of Surgery 1st Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Department of Nephrology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2017;129:242–58. 10.1080/00325481.2017.1246055 PubMed DOI

Kirby WM, Clarke JT, Libke RDet al. . Clinical pharmacology of amikacin and kanamycin. J Infect Dis 1976;134 Suppl:S312–5. 10.1093/infdis/135.Supplement_2.S312 PubMed DOI

Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974;6:465–70. 10.1128/AAC.6.4.465 PubMed DOI PMC

Riff LJ, Jackson GG. Pharmacology of gentamicin in man. J Infect Dis 1971;124 Suppl:S98–105. 10.1093/infdis/124.Supplement_1.S98 PubMed DOI

Fang GD, Brennen C, Wagener Met al. . Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991;35:1849–55. 10.1128/AAC.35.9.1849 PubMed DOI PMC

Sima M, Hartinger J, Cikankova Tet al. . Estimation of once-daily amikacin dose in critically ill adults. J Chemother 2018;30:37–43. PubMed

Baudoux P, Bles N, Lemaire Set al. . Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 2007;59:246–53. 10.1093/jac/dkl489 PubMed DOI

Gudmundsson A, Erlendsdottir H, Gottfredsson Met al. . Impact of pH and cationic supplementation on in vitro postantibiotic effect. Antimicrob Agents Chemother 1991;35:2617–24. 10.1128/AAC.35.12.2617 PubMed DOI PMC

Minuth JN, Musher DM, Thorsteinsson SB. Inhibition of the antibacterial activity of gentamicin by urine. J Infect Dis 1976;133:14–21. 10.1093/infdis/133.1.14 PubMed DOI

Melinda Monteforte BS. Aminoglycoside dosing and monitoring guidelines for adult patients at Stony Brook University Hospital. 2015, 14p. https://www.stonybrookmedicine.edu/sites/default/files/amino.pdf (15 January 2024, date last accessed).

Stankowicz MS, Ibrahim J, Brown DL. Once-daily aminoglycoside dosing: an update on current literature. Am J Health Syst Pharm 2015;72:1357–64. 10.2146/ajhp140564 PubMed DOI

Halouzková BA, Hartinger JM, Krátký Vet al. . Dosing of aminoglycosides in chronic kidney disease and end-stage renal disease patients treated with intermittent hemodialysis. Kidney Blood Press Res 2022;47:448–58. 10.1159/000523892 PubMed DOI

Wise R, Andrews JM. The bactericidal activity of gatifloxacin in plasma and urine. Clin Microbiol Infect 1998;4:392–6. 10.1111/j.1469-0691.1998.tb00083.x PubMed DOI

Stamey TA, Fair WR, Timothy MMet al. . Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med 1974;291:1159–63. 10.1056/NEJM197411282912204 PubMed DOI

Sachs J, Geer T, Noell Pet al. . Effect of renal function on urinary recovery of orally administered nitrofurantoin. N Engl J Med 1968;278:1032–5. 10.1056/NEJM196805092781902 PubMed DOI

Bailey RR, Peddie B, McRae CU. Antibiotic concentrations in the urine from kidneys of unequal function. Clin Nephrol 1982;17:258–61. PubMed

Stamey TA, Govan DE, Palmer JM. The localization and treatment of urinary tract infections: the role of bactericidal urine levels as opposed to serum levels. Medicine (Baltimore) 1965;44:1–36. 10.1097/00005792-196501000-00001 PubMed DOI

Giua R, Pedone C, Cortese Let al. . Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature. Infection 2014;42:199–202. 10.1007/s15010-013-0507-y PubMed DOI

Bilsen MP, van Uhm JIM, Stalenhoef JEet al. . Intravesical aminoglycoside instillations as prophylaxis for recurrent urinary tract infection: patient satisfaction, long-term safety and efficacy. JAC Antimicrob Resist 2023;5:dlad040. 10.1093/jacamr/dlad040 PubMed DOI PMC

Zacharias S, Dwarakanath S, Agarwal Met al. . A comparative study to assess the effect of amikacin sulfate bladder wash on catheter-associated urinary tract infection in neurosurgical patients. Indian J Crit Care Med 2009;13:17–20. 10.4103/0972-5229.53110 PubMed DOI PMC